The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: channa striata and curcuma, Maltodextrin (Placebo).
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: No limits · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Indonesia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Breast cancer is frequently accompanied by chronic inflammation, malnutrition, and reduced quality of life, all of which may compromise treatment response and clinical outcomes. Nutritional interventions with immunomodulatory and anti-inflammatory properties have the potential to improve these conditions. Channa striata is rich in high-quality protein, albumin, and essential amino acids that support nutritional recovery and tissue repair, while Curcuma contains curcumin, a bioactive compound with well-established anti-inflammatory and antioxidant effects. This study aims to evaluate the effect of combined Channa striata and Curcuma supplementation on nutritional status, serum interleukin-6 (IL-6) levels, and quality of life in patients with breast cancer undergoing treatment. The findings are expected to provide evidence for the use of this nutritional supplementation as a complementary strategy to improve clinical outcomes, reduce systemic inflammation, and enhance the overall well-being of breast cancer patients.
Interventions
- Dietary supplement channa striata and curcuma
Participants in the intervention group received oral supplementation consisting of 5 g of Channa striata and 250 mg of Curcuma daily for one month, while participants in the control group received a maltodextrin placebo daily for the same duration. - Dietary supplement Maltodextrin (Placebo)
Participants in the control group received a placebo consisting of maltodextrin daily for one month.
Primary outcome measures
- Nutritional status [Time frame: baseline post intervention 4 weeks]
Secondary outcome measures (1)
- interleukin - 6 [Time frame: Baseline and 1 month after intervention]
Eligibility criteria
Inclusion criteria
- Female patients with breast cancer aged ≥18 years who were undergoing chemotherapy.
- Patients with a body mass index (BMI) of 18-29 kg/m².
- Patients currently receiving chemotherapy for breast cancer.
- Patients with serum albumin levels of 2.0-3.5 g/dL.
- Patients who were able to consume oral food and were willing to participate in the study by providing written informed consent.
Exclusion criteria
- Patients with chronic kidney disease, renal failure, or kidney infection.
- Patients with a known allergy to fish or Channa striata (snakehead fish) albumin-derived products.
- Patients receiving other protein or amino acid supplements during the study period.
- Patients who were non-compliant or discontinued the intervention before completion of the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Supportive care
Study locations
Indonesia · 1 center
- Nutrition Department — Medan
Identifiers
NCT: NCT07722156 · USU Onchology Nutrition